ReviewCureus2025
Efficacy and Safety of Colchicine in Reducing Reperfusion Injury Among Patients With ST-Segment Elevation Myocardial Infarction (STEMI): A Systematic Review and Clinical Appraisal.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Irreversible March of Time: Ischemic Delay and Impact on Outcomes in ST-Segment Elevation Myocardial Infarction.Journal of cardiovascular development and disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review evaluated the efficacy and safety of colchicine in reducing ischemia-reperfusion injury among patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. A comprehensive literature search across five databases identified 92 records, with five studies meeting the inclusion criteria, encompassing 390 patients. The included studies comprised randomized controlled trials and prospective studies investigating various colchicine dosing regimens, from short-term high-dose protocols to prolonged maintenance therapy. Primary outcomes included infarct size, inflammatory biomarkers, major adverse cardiovascular events, and safety profiles. Results demonstrated heterogeneous findings across studies. While one trial showed trends toward reduced inflammatory markers such as NLRP3 inflammasome activity, others failed to demonstrate significant reductions in reperfusion injury events or infarct size. Notably, the COVERT-MI trial revealed an unexpected threefold increase in left ventricular thrombus formation with colchicine therapy, raising safety concerns. Gastrointestinal side effects were also consistently reported across studies. The evidence suggests that the anti-inflammatory properties of colchicine may not translate into clinically meaningful cardioprotection in the acute phase of STEMI. Current data do not support routine colchicine administration for reperfusion injury reduction in STEMI patients undergoing primary percutaneous coronary intervention, highlighting the need for larger, well-designed trials with standardized protocols and longer follow-up periods to definitively establish its role in acute myocardial infarction management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.